Printer Friendly

Epimmune to Present at BIO CEO & Investor Conference 2002 With Simultaneous Webcast.

SAN DIEGO -- Epimmune Inc. today announced that its presentation at the BIO CEO & Investor Conference 2002 will be webcast live and may be accessed at http://www.epimmune.com/webcast /.

Emile Loria, M.D., President and Chief Executive Officer of Epimmune, will provide an overview of the Company. The presentation is scheduled to take place on Wednesday, February 20, 2002 at 10:50 a.m. ET (7:50 a.m. PT) from the Waldorf-Astoria in New York City.

Following the live presentation, the webcast will be archived for approximately thirty days and can be accessed at the above referenced address beginning approximately one hour after the live presentation.

Epimmune Overview

Epimmune Inc. is a leader in using gene maps of cancer-associated proteins and infectious agents to design vaccines that induce cellular immunity. Epimmune's technology platform is based on its pioneering work in deciphering the genetic code which regulates T-cell activation and in identifying antigen fragments known as epitopes which can activate highly targeted T-cell responses to tumors, viruses, bacteria and parasites. This new field of pharmacology opens two significant areas of pharmaceutical development: protective vaccines that activate T-cell protection against infections, such as HIV and hepatitis C, and therapeutic vaccines designed to stimulate antigen-specific T-cell responses to infections, such as HIV, hepatitis C and hepatitis B, and tumors such as breast, colon, lung and prostate. For more information on Epimmune, visit http://www.epimmune.com/ .

This press release includes forward-looking statements that reflect management's current views of future events. Actual results may differ materially from the above forward-looking statements due to a number of important factors, including but not limited to the risks associated with the Company's ability to develop vaccines using epitopes, the ability of epitope-based vaccines to control infectious diseases and cancer, the safety and efficacy of epitope-based vaccines in humans, the Company's ability to enter into and maintain new collaborations and to license our technology, the efforts of the Company's collaborators and licensees to develop and commercialize products using the Company's technologies, achievement of research and development objectives by the Company and any collaborator, the timing and cost of conducting human clinical trials, the regulatory approval process, and the possibility that testing may reveal undesirable and unintended side effects or other characteristics that may prevent or limit the commercial use of proposed products. These factors are more fully discussed in the Company's 2000 Form 10-K, the most recent 10-Qs and other periodic reports filed with the Securities and Exchange Commission.

MAKE YOUR OPINION COUNT - Click Here

http://tbutton.prnewswire.com/prn/11690X78872059

Contact: Robert De Vaere, VP, Finance & Admin. & CFO of Epimmune Inc., +1-858-860-2553; or Media, Amber Meager of Susan E. Atkins & Associates, +1-858-860-0266, for Epimmune Inc.

Website: http://www.epimmune.com/ http://www.epimmune.com/webcast
COPYRIGHT 2002 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Geographic Code:1USA
Date:Feb 18, 2002
Words:460
Previous Article:Prime Therapeutics Names Dr. Philip Olson as Interim CEO.
Next Article:Ribozyme Pharmaceuticals to Present at the 14th Annual Roth Capital Partners Growth Stock Conference.
Topics:


Related Articles
Cell Therapeutics, Inc. Presents at Investor Conferences in February.
Hyseq Pharmaceuticals to Present at the BIO CEO & Investor Conference On February 20, 2002.
Neurogen Corporation to Present at BIO CEO & Investor Conference February 22, 2002.
Genome Therapeutics to Present at the Annual BIO CEO & Investors Conference.
Aradigm Corporation to Present at The BIO CEO & Investor Conference In New York.
Genome Therapeutics To Present at the Annual BIO 2002 International Biotechnology Convention and Exhibition.
Micrologix to Present at BIO 2002; Tuesday, June 11, 2002 - 10:15AM EDT - Web Cast Notification.
Epimmune to Present at Rodman & Renshaw Techvest 6th Annual Healthcare Conference.
Vertex Pharmaceuticals Announces Webcast of its Presentations at Two Investor Conferences.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters